{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:41Z","timestamp":1791919661404,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Poly (ADP-ribose) polymerase (PARP) inhibitor and antiangiogenic agent monotherapy have shown to be effective as maintenance treatment in patients with ovarian cancer (OC). However, there is currently a lack of evidence-based study to directly compare the effects of combination therapy with these two drugs. Therefore, this study aimed to compare the efficacy and safety of combination therapy with PARP inhibitors and antiangiogenic agents in women with OC using a meta-analysis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> An exhaustive search of literature was undertaken using multiple databases, including PubMed, Web of Science, Embase, and the Cochrane Library to identify pertinent randomized controlled trials (RCTs) published up until 17 December 2023. The data on progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were pooled. We computed the pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for PFS and OS, along with the relative risks (RRs) and 95% CIs for AEs. Trial sequential analysis, heterogeneity test, sensitivity analysis, and publication bias assessment were performed. Stata 12.0 and Software R 4.3.1 were utilized for all analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> This meta-analysis included 7 RCTs with a total of 3,388 participants. The overall analysis revealed that combination therapy of PARP inhibitors and antiangiogenic agents significantly improved PFS (HR = 0.615, 95% CI = 0.517\u20130.731; 95% PI = 0.379\u20130.999), but also increased the risk of AEs, including urinary tract infection (RR = 1.500, 95% CI = 1.114\u20132.021; 95% PI = 0.218\u201310.346), fatigue (RR = 1.264, 95% CI = 1.141\u20131.400; 95% PI = 1.012\u20131.552), headache (RR = 1.868, 95% CI = 1.036\u20133.369; 95% PI = 0.154\u201322.642), anorexia (RR = 1.718, 95% CI = 1.320\u20132.235; 95% PI = 0.050\u201365.480), and hypertension (RR = 5.009, 95% CI = 1.103\u201322.744; 95% PI = 0.016\u20131580.021) compared with PARP inhibitor or antiangiogenic agent monotherapy. Our study has not yet confirmed the benefit of combination therapy on OS in OC patients (HR = 0.885, 95% CI = 0.737\u20131.063). Additionally, subgroup analyses further showed that combination therapy resulted in an increased risk of AEs, encompassing thrombocytopenia, vomiting, abdominal pain, proteinuria, fatigue, headache, anorexia, and hypertension (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study demonstrated the PFS benefit of combination therapy with PARP inhibitors and antiangiogenic agents in patients with OC. The OS result need to be updated after the original trial data is mature. Clinicians should be vigilant of AEs when administering the combination therapy in clinical practice.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier CRD42023494482.<\/jats:p>","DOI":"10.3389\/fphar.2024.1372077","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T04:25:05Z","timestamp":1711081505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000320579","article-title":"Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma","volume":"78","author":"Abaid","year":"2010","journal-title":"Oncology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/thno.21674","article-title":"Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics","volume":"8","author":"Abdalla","year":"2018","journal-title":"Theranostics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","article-title":"Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review","volume":"162","author":"Alvarez Secord","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1128\/mcb.24.19.8504-8518.2004","article-title":"Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2288-11-41","article-title":"Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics","volume":"11","author":"Bowden","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","article-title":"Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature","volume":"34","author":"Capriglione","year":"2017","journal-title":"Med. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1158\/1078-0432.Ccr-10-0527","article-title":"Contextual\" synthetic lethality and\/or loss of heterozygosity: tumor hypoxia and modification of DNA repair","volume":"16","author":"Chan","year":"","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1158\/0008-5472.Can-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/s1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"Cd005343","DOI":"10.1002\/14651858.CD005343.pub5","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","volume":"2","author":"Coleridge","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.celrep.2018.11.054","article-title":"PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer","volume":"25","author":"Ding","year":"2018","journal-title":"Cell Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1007\/s12325-019-01106-1","article-title":"Comparison of PARPis with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network meta-analysis","volume":"36","author":"Feng","year":"2019","journal-title":"Adv. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"Springerplus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/s0090-8258(21)00679-x","article-title":"Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab","volume":"162","author":"Hardesty","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","article-title":"Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130","volume":"107","author":"Hegan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17588359231173183","DOI":"10.1177\/17588359231173183","article-title":"The role of PARP inhibitor combination therapy in ovarian cancer","volume":"15","author":"Hockings","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.Mcr-18-0138","article-title":"PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/13543784.2016.1156857","article-title":"Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer","volume":"25","author":"Ivy","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin. Trials"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cells8091102","article-title":"Trends and challenges in tumor anti-angiogenic therapies","volume":"8","author":"J\u00e1szai","year":"2019","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2217\/fon-2021-0059","article-title":"Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer","volume":"17","author":"Le Saux","year":"2021","journal-title":"Future Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/s1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1200\/jco.2020.38.15_suppl.6003","article-title":"A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"38","author":"Liu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/jco.21.02011","article-title":"Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1200\/jco.2020.38.15_suppl.6039","article-title":"Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial","volume":"38","author":"Lorusso","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","article-title":"Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg\/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/jco.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/s1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/jco.2020.38.15_suppl.6012","article-title":"Final survival analysis of NSGO-AVANOVA2\/ENGOT-OV24: combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer-A randomized controlled chemotherapy-free study","volume":"38","author":"Mirza","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fonc.2014.00042","article-title":"Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors","volume":"4","author":"O'Sullivan","year":"2014","journal-title":"Front. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/s1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"638295","DOI":"10.3389\/fonc.2021.638295","article-title":"Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"11","author":"Ren","year":"2021","journal-title":"Front. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2022.11.029","article-title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged \u226565 years from the PAOLA-1\/ENGOT-ov25 trial","volume":"181","author":"Sabatier","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/gco.0000000000000931","article-title":"Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives","volume":"36","author":"Salutari","year":"2024","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/j.ejca.2007.07.010","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis","volume":"43","author":"Tentori","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1158\/1078-0432.Ccr-17-0874","article-title":"Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis","volume":"23","author":"Ueda","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejca.2021.08.023","article-title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1\/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","volume":"157","author":"Vergote","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13048-021-00843-8","article-title":"Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression","volume":"14","author":"Wang","year":"2021","journal-title":"J. Ovarian Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.3892\/ol.2016.5226","article-title":"PARP-1 may be involved in angiogenesis in epithelial ovarian cancer","volume":"12","author":"Wei","year":"2016","journal-title":"Oncol. Lett."},{"key":"B58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med. Res. Methodol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1039320","DOI":"10.3389\/fonc.2022.1039320","article-title":"Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"12","author":"Xie","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372077\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T04:25:09Z","timestamp":1711081509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1372077\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":59,"alternative-id":["10.3389\/fphar.2024.1372077"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1372077","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"article-number":"1372077"}}